An observational study evaluated patient characteristics and overall survival in post-docetaxel metastatic castration-resistant prostate cancer patients.

Trial Profile

An observational study evaluated patient characteristics and overall survival in post-docetaxel metastatic castration-resistant prostate cancer patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2016

At a glance

  • Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2016 New trial record
    • 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top